Ohr Pharmaceutical, Inc. (NASDAQ:OHRP)

Monday, June 18, 2012 | Web News
NEW YORK, NY--(Marketwire - May 14, 2012) - Ohr Pharmaceutical Inc. (OTCBB: OHRP) announced today that its Squalamine...
See All Research...

OHR Pharmaceutical, Inc. operates as a biotechnology company. The company’s product line comprises Squalamine, an anti-angiogenic small molecule with a novel intracellular mechanism of action that counteracts not only vascular endothelial growth factor but also other angiogenic growth factors, including platelet derived growth factor and basic fibroblast growth factor. It also focuses on the development of OHR/AVR 118 for the treatment of cancer cachexia, a multi-symptom wasting disorder characterized by weight loss, muscle atrophy, fatigue, weakness, and significant loss of appetite. The company is headquartered in New York, New York.

Last updated June 18, 2012